# Zotarolimus vs Sirolimus Eluting Stent in High Bleeding Risk

Study · id `cardio:ct-nct05240781` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05240781](<https://clinicaltrials.gov/study/NCT05240781>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05240781

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 280 participants.

## Technical summary

Registry record NCT05240781. Randomized; double masking; primary purpose treatment. Start 2021-09-29 (actual); primary completion 2024-02-28 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 280 participants (planned count; ClinicalTrials.gov record NCT05240781, source copy `cardio:ctgov-nct05240781-2022-03-04`, retrieved 2026-10-26)
- Started: 2021-09-29 (actual) (ClinicalTrials.gov record NCT05240781, source copy `cardio:ctgov-nct05240781-2022-03-04`, retrieved 2026-10-26)
- Primary completion: 2024-02-28 (anticipated) (ClinicalTrials.gov record NCT05240781, source copy `cardio:ctgov-nct05240781-2022-03-04`, retrieved 2026-10-26)
- Completion: 2025-02-28 (anticipated) (ClinicalTrials.gov record NCT05240781, source copy `cardio:ctgov-nct05240781-2022-03-04`, retrieved 2026-10-26)
- Countries: Mexico (ClinicalTrials.gov record NCT05240781, source copy `cardio:ctgov-nct05240781-2022-03-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05240781-2022-03-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Zotarolimus vs Sirolimus Eluting Stent in High Bleeding Risk
- Acronym: ZEVS-HBR
- Condition: High Bleeding Risk
- Condition: Coronary Artery Disease
- Condition: Percutaneous Coronary Intervention
- Intervention (Device): Zotarolimus eluting stent
- Intervention (Device): Sirolimus eluting stent
- Lead sponsor: Instituto Nacional de Cardiologia Ignacio Chavez
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Instituto Nacional de Cardiologia Ignacio Chavez (`cardio:org-instituto-nacional-de-cardiologia-ignacio-chavez`)

## Provenance

Content hash: a608a22d0df4b6d511ac4bbec7dd0400e7c65b45c025a9ff9c28ba738cdb82fe
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
